|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chi KN, Bjartell A, Dearnaley D, Saad F,
Schröder FH, Sternberg C, Tombal B and Visakorpi T:
Castration-resistant prostate cancer: From new pathophysiology to
new treatment targets. Eur Urol. 56:594–605. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun Y, Wang BE, Leong KG, Yue P, Li L,
Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen
deprivation causes epithelial-mesenchymal transition in the
prostate: Implications for androgen-deprivation therapy. Cancer
Res. 72:527–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grommes C, Landreth GE and Heneka MT:
Antineoplastic effects of peroxisome proliferator-activated
receptor gamma agonists. Lancet Oncol. 5:419–429. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weng JR, Chen CY, Pinzone JJ, Ringel MD
and Chen CS: Beyond peroxisome proliferator-activated receptor
gamma signaling: The multi-facets of the antitumor effect of
thiazolidinediones. Endocr Relat Cancer. 13:401–413. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei S, Yang J, Lee SL, Kulp SK and Chen
CS: PPARgamma-independent antitumor effects of thiazolidinediones.
Cancer Lett. 276:119–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HN, Lee YR, Noh EM, Lee KS, Kim JS,
Song EK, Han MK, Lee YC, Kwon KB, Lee SJ, et al: Induction of G1
phase arrest and apoptosis in MDA-MB-231 breast cancer cells by
troglitazone, a synthetic peroxisome proliferator-activated
receptor gamma (PPARgamma) ligand. Cell Biol Int. 32:906–912. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Colin-Cassin C, Yao X, Cerella C, Chbicheb
S, Kuntz S, Mazerbourg S, Boisbrun M, Chapleur Y, Diederich M,
Flament S and Grillier-Vuissoz I: PPARγ-inactive Δ2-troglitazone
independently triggers ER stress and apoptosis in breast cancer
cells. Mol Carcinog. 54:393–404. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye J, Yin L, Xie P, Wu J, Huang J, Zhou G,
Xu H, Lu E and He X: Antiproliferative effects and molecular
mechanisms of troglitazone in human cervical cancer in vitro. Onco
Targets Ther. 8:1211–1218. 2015.PubMed/NCBI
|
|
10
|
Li MY, Deng H, Zhao JM, Dai D and Tan XY:
PPARgamma pathway activation results in apoptosis and COX-2
inhibition in HepG2 cells. World J Gastroenterol. 9:1220–1226.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang SN, Han J, Abdelkader TS, Kim TH,
Lee JM, Song J, Kim KS and Park JH and Park JH: High animal fat
intake enhances prostate cancer progression and reduces glutathione
peroxidase 3 expression in early stages of TRAMP mice. Prostate.
74:1266–1277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shiau CW, Yang CC, Kulp SK, Chen KF and
Chen CS, Huang JW and Chen CS: Thiazolidenediones mediate apoptosis
in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2
functions independently of PPARgamma. Cancer Res. 65:1561–1569.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santha S, Viswakarma N, Das S, Rana A and
Rana B: Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-troglitazone-induced apoptosis in prostate cancer cells
involve AMP-activated protein kinase. J Biol Chem. 290:21865–21875.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mueller E, Smith M, Sarraf P, Kroll T,
Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, et al:
Effects of ligand activation of peroxisome proliferator-activated
receptor gamma in human prostate cancer. Proc Natl Acad Sci USA.
97:10990–10995. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burstein HJ, Demetri GD, Mueller E, Sarraf
P, Spiegelman BM and Winer EP: Use of the peroxisome
proliferator-activated receptor (PPAR) gamma ligand troglitazone as
treatment for refractory breast cancer: A phase II study. Breast
Cancer Res Treat. 79:391–397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kulke MH, Demetri GD, Sharpless NE, Ryan
DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ and
Fuchs CS: A phase II study of troglitazone, an activator of the
PPARgamma receptor, in patients with chemotherapy-resistant
metastatic colorectal cancer. Cancer J. 8:395–399. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Christofori G: New signals from the
invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frixen UH, Behrens J, Sachs M, Eberle G,
Voss B, Warda A, Löchner D and Birchmeier W: E-cadherin-mediated
cell-cell adhesion prevents invasiveness of human carcinoma cells.
J Cell Biol. 113:173–185. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Day C: Thiazolidinediones: A new class of
antidiabetic drugs. Diabet Med. 16:179–192. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikezoe T, Miller CW, Kawano S, Kawano S,
Heaney A, Williamson EA, Hisatake J, Green E, Hofmann W, Taguchi H
and Koeffler HP: Mutational analysis of the peroxisome
proliferator-activated receptor gamma gene in human malignancies.
Cancer Res. 61:5307–5310. 2001.PubMed/NCBI
|
|
24
|
Matsuyama M and Yoshimura R: Peroxisome
proliferator-activated receptor-gamma is a potent target for
prevention and treatment in human prostate and testicular cancer.
PPAR Res. 2008:2498492008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sikka S, Chen L, Sethi G and Kumar AP:
Targeting PPARgamma signaling cascade for the prevention and
treatment of prostate cancer. PPAR Res. 2012:9680402012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshizumi T, Ohta T, Ninomiya I, Terada I,
Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S and Miwa K:
Thiazolidinedione, a peroxisome proliferator-activated
receptor-gamma ligand, inhibits growth and metastasis of HT-29
human colon cancer cells through differentiation-promoting effects.
Int J Oncol. 25:631–639. 2004.PubMed/NCBI
|
|
27
|
Takano S, Kubota T, Nishibori H, Hasegawa
H, Ishii Y, Nitori N, Ochiai H, Okabayashi K, Kitagawa Y, Watanabe
M and Kitajima M: Pioglitazone, a ligand for peroxisome
proliferator-activated receptor-gamma acts as an inhibitor of colon
cancer liver metastasis. Anticancer Res. 28:3593–3599.
2008.PubMed/NCBI
|
|
28
|
Shen B, Chu ES, Zhao G, Man K, Wu CW,
Cheng JT, Li G, Nie Y, Lo CM, Teoh N, et al: PPARgamma inhibits
hepatocellular carcinoma metastases in vitro and in mice. Br J
Cancer. 106:1486–1494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee HJ, Su Y, Yin PH, Lee HC and Chi CW:
PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and
motility of HepG2 cells. Anticancer Res. 29:5057–5063.
2009.PubMed/NCBI
|
|
30
|
Magenta G, Borenstein X, Rolando R and
Jasnis MA: Rosiglitazone inhibits metastasis development of a
murine mammary tumor cell line LMM3. BMC Cancer. 8:472008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu H, Zang C, Fenner MH, Possinger K and
Elstner E: PPARgamma ligands and ATRA inhibit the invasion of human
breast cancer cells in vitro. Breast Cancer Res Treat. 79:63–74.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK,
Kim SH, Kim IS, Hong JT, Sung JH, Son BC and Lee SW: E-cadherin as
a predictive marker of brain metastasis in non-small-cell lung
cancer, and its regulation by pioglitazone in a preclinical model.
J Neurooncol. 109:219–227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang DR, Lin SJ, Ding XF, Miyamoto H,
Messing E, Li LQ, Wang N and Chang C: Higher expression of
peroxisome proliferator-activated receptor γ or its activation by
agonist thiazolidinedione-rosiglitazone promotes bladder cancer
cell migration and invasion. Urology. 81:1109.e1–e6. 2013.
View Article : Google Scholar
|
|
34
|
Qin L, Gong C, Chen AM, Guo FJ, Xu F, Ren
Y and Liao H: Peroxisome proliferatoractivated receptor γ agonist
rosiglitazone inhibits migration and invasion of prostate cancer
cells through inhibition of the CXCR4/CXCL12 axis. Mol Med Rep.
10:695–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brigelius-Flohé R and Maiorino M:
Glutathione peroxidases. Biochim Biophys Acta. 1830:3289–3303.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao H, Li J, Li X, Han C, Zhang Y, Zheng
L and Guo M: Silencing GPX3 expression promotes tumor metastasis in
human thyroid cancer. Curr Protein Pept Sci. 16:316–321. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Peng DF, Hu TL, Schneider BG, Chen Z, Xu
ZK and El-Rifai W: Silencing of glutathione peroxidase 3 through
DNA hypermethylation is associated with lymph node metastasis in
gastric carcinomas. PLoS One. 7:e462142012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Murawaki Y, Tsuchiya H, Kanbe T, Harada K,
Yashima K, Nozaka K, Tanida O, Kohno M, Mukoyama T, Nishimuki E, et
al: Aberrant expression of selenoproteins in the progression of
colorectal cancer. Cancer Lett. 259:218–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Agnani D, Camacho-Vanegas O, Camacho C,
Lele S, Odunsi K, Cohen S, Dottino P and Martignetti JA: Decreased
levels of serum glutathione peroxidase 3 are associated with
papillary serous ovarian cancer and disease progression. J Ovarian
Res. 4:182011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brigelius-Flohé R and Kipp A: Glutathione
peroxidases in different stages of carcinogenesis. Biochim Biophys
Acta. 1790:1555–1568. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen B, Rao X, House MG, Nephew KP, Cullen
KJ and Guo Z: GPx3 promoter hypermethylation is a frequent event in
human cancer and is associated with tumorigenesis and chemotherapy
response. Cancer Lett. 309:37–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He Y, Wang Y, Li P, Zhu S, Wang J and
Zhang S: Identification of GPX3 epigenetically silenced by CpG
methylation in human esophageal squamous cell carcinoma. Dig Dis
Sci. 56:681–688. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mohamed MM, Sabet S, Peng DF, Nouh MA,
El-Shinawi M and El-Rifai W: Promoter hypermethylation and
suppression of glutathione peroxidase 3 are associated with
inflammatory breast carcinogenesis. Oxid Med Cell Longev.
2014:7871952014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee OJ, Schneider-Stock R, McChesney PA,
Kuester D, Roessner A, Vieth M, Moskaluk CA and El-Rifai W:
Hypermethylation and loss of expression of glutathione peroxidase-3
in Barrett's tumorigenesis. Neoplasia. 7:854–861. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lodygin D, Epanchintsev A, Menssen A,
Diebold J and Hermeking H: Functional epigenomics identifies genes
frequently silenced in prostate cancer. Cancer Res. 65:4218–4227.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu YP, Yu G, Tseng G, Cieply K, Nelson J,
Defrances M, Zarnegar R, Michalopoulos G and Luo JH: Glutathione
peroxidase 3, deleted or methylated in prostate cancer, suppresses
prostate cancer growth and metastasis. Cancer Res. 67:8043–8050.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sekine Y, Osei-Hwedieh D, Matsuda K,
Raghavachari N, Liu D, Furuya Y, Koike H, Suzuki K and Remaley AT:
High fat diet reduces the expression of glutathione peroxidase 3 in
mouse prostate. Prostate. 71:1499–1509. 2011.PubMed/NCBI
|
|
49
|
Wang H, Luo K, Tan LZ, Ren BG, Gu LQ,
Michalopoulos G, Luo JH and Yu YP: p53-induced gene 3 mediates cell
death induced by glutathione peroxidase 3. J Biol Chem.
287:16890–16902. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chang SN, Lee JM, Oh H and Park JH:
Glutathione peroxidase 3 inhibits prostate tumorigenesis in TRAMP
mice. Prostate. 76:1387–1398. 2016. View Article : Google Scholar : PubMed/NCBI
|
